南财智讯1月30日电，广生堂发布2025年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 亏损1.70亿元—2.40亿元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损 1.78亿元—2.48亿元。本报告期内，公司业绩亏损主要影响原因如下：1、报告期内，公司始终坚持创新 药发展战略，持续研发投入以快速推进创新药临床研究，且受前期固定资产投资较大等因素影响，公司 研发费用和管理费用保持在较高水平。截止目前，在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III 期临床试验已完成526例受试者入组，达到临床方案设定的计划目标入组数，后续将继续推进受试者入 组工作，预计于2026年2月中旬完成全部入组，最终入组人数可能在原计划目标基础上有少部分增加。 创新药研发周期长，投入大，风险高，容易受到多方面因素的影响，临床研究存在研究进度和结果不及 预期甚至失败的风险，后续能否获得批准存在不确定性。敬请广大投资者谨慎决策，注意防范投资风 险。2、公司基于谨慎性原则，对报告期末合并报表范围内无形资产、存货、固定资产等资产进行减值 测试，对发生减值的资产计提减值准备。3、报告期内，预计非经常 ...

Financial Performance - The company expects a net loss of between 170 million and 240 million yuan for the fiscal year 2025, compared to a loss of 156.30 million yuan in the same period last year[3] - The net loss after deducting non-recurring gains and losses is projected to be between 177.50 million and 247.50 million yuan, compared to a loss of 199.54 million yuan in the previous year[3] - The company anticipates a reduction of approximately 35.73 million yuan in non-recurring gains and losses, primarily due to a significant decrease in government subsidies[6] Investment and Development - The primary reason for the loss is the ongoing investment in innovative drug development, with significant R&D and management expenses due to prior fixed asset investments[5] - The clinical trial for the innovative hepatitis B treatment drug GST-HG141 has enrolled 526 participants, meeting the planned target, with full enrollment expected by mid-February 2026[5] Asset Management - The company is conducting impairment tests on intangible assets, inventory, and fixed assets, with provisions for impairment being made[6] Caution for Investors - The final financial data for the fiscal year 2025 will be disclosed in the annual report, and investors are advised to exercise caution[7]

Core Viewpoint - The company emphasizes the significant unmet clinical needs in the treatment of chronic hepatitis B, highlighting the market opportunities presented by the Chinese government's action plan for viral hepatitis prevention and treatment from 2025 to 2030 [1] Group 1: Market Opportunity - There is a large global patient base for chronic hepatitis B, indicating substantial unmet clinical demand [1] - The Chinese action plan aims for a diagnosis rate of over 80% for chronic hepatitis B patients and an antiviral treatment rate of over 80% for newly reported patients by 2030, creating a favorable environment for innovative drug development [1] Group 2: Company Strategy - The company is committed to addressing the significant unmet clinical needs in hepatitis B treatment and is actively advancing the clinical development of related innovative drugs [1] - The company aims to validate the product's value with confirmed clinical data and apply for market approval as soon as possible, expressing confidence in the market post-launch [1] Group 3: R&D Challenges - The research and development cycle for innovative drugs is long, requires substantial investment, and carries high risks [1]

广生堂（300436.SZ）1月28日在投资者互动平台表示，GST-HG141的III期临床整体入组进度已顺利过 半。公司团队正持续高效推进患者招募入组工作，全力保障临床进展，力争尽早达成计划入组目标。后 续重要进展公司将及时履行信息披露，敬请关注。 每经AI快讯，有投资者在投资者互动平台提问：公司GST-HG141作为全球首个进入III期的II型核心蛋白 变构调节剂，目前全国50余家临床中心入组进度是否已超50%？后续入组是否会提前完成？ （记者 张明双） ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300436 | 广生堂 | 105.01 | 14.00% | 21.58万 | | 22.03亿 | | 300765 | 新诺威 | 46.21 | 12.90% | 23.06万 | | 10.27亿 | | 688428 | 诺诚健华 | 20.39 | 2.05% | 6.96万 | | 1.41亿 | | 300401 | 化园生物 | 17.71 | 1.84% | P 29.42万 | | 5.24亿 | | 688192 | 迪哲医药 | 58.96 | 1.78% | 2.60万 | | 1.52亿 | | 002099 | 海翔药业 | 6.35 | 1.28% | 33.69万 | | 2.14亿 | | 688578 | 文力斯 | 101.30 | 1.25% | 4.40万 | | 4.40 乙 | | 300573 | 兴齐眼药 | 72.10 | 1.22% | 8.25万 | | 5.96亿 | ...

中欧医疗健康混合A（003095）基金经理为葛兰、赵磊。 1月28日，广生堂涨5.66%，截至发稿，报97.32元/股，成交4.67亿元，换手率3.64%，总市值155.00亿 元。 资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号楼，成立日期2001年6月28日，上市日期2015年4月22日，公司主营业务涉 及核苷类抗乙肝病毒药物的研发、生产与销售。主营业务收入构成为：肝胆疾病药物98.54%，其他(补 充)1.46%。 从广生堂十大流通股东角度 数据显示，中欧基金旗下1只基金位居广生堂十大流通股东。中欧医疗健康混合A（003095）三季度减 持113.65万股，持有股数70.81万股，占流通股的比例为0.52%。根据测算，今日浮盈赚取约368.95万 元。 中欧医疗健康混合A（003095）成立日期2016年9月29日，最新规模138.43亿。今年以来收益2.06%，同 类排名6843/8864；近一年收益19.88%，同类排名5406/8126；成立以来收益99.16%。 截至发稿，葛兰累计任职时间11年3天，现任基金资产总规模35 ...

证券之星消息，1月27日化学制药板块较上一交易日下跌0.97%，广生堂领跌。当日上证指数报收于 4139.9，上涨0.18%。深证成指报收于14329.91，上涨0.09%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301089 | 拓新药业 | 34.37 | 7.98% | 18.06万 | | 5.92亿 | | 000952 | 广济药业 | 8.26 | 6.03% | 55.28万 | | 4.36亿 | | 300765 | 新诺威 | 40.93 | 5.41% | 12.05万 | | 4.83亿 | | 603229 | 奧翔药业 | 10.45 | 4.40% | - 36.29万 | | 3.70亿 | | 688176 | 亚斯医药 | 14.56 | 4.30% | 17.36万 | | 2.51亿 | | 301263 | 泰恩康 | 34.45 | 3.30% | 11.27万 | | 3.86亿 | | 688 ...

Group 1 - The chemical pharmaceutical sector increased by 0.91% on January 23, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] - Guangshantang's stock price rose by 20.00% to 96.28, with a trading volume of 185,500 shares [1] Group 2 - The main funds in the chemical pharmaceutical sector experienced a net outflow of 487 million yuan, while retail investors saw a net inflow of 1.12 billion yuan [2] - The stock performance of several companies showed varied results, with some experiencing declines, such as Xingqi Eye Medicine down 4.86% [2] - The trading volume and turnover for various companies in the sector were significant, with notable figures such as 1.62 billion yuan for Xingqi Eye Medicine [2] Group 3 - Guangshantang had a net inflow of 396 million yuan from main funds, while retail investors had a net outflow of 136 million yuan [3] - Other companies like Hancheng Group and Shutaishen also showed significant net inflows and outflows, indicating varied investor sentiment [3] - The data reflects a mixed investment environment within the chemical pharmaceutical sector, with both institutional and retail investors actively participating [3]

Group 1 - The Shanghai Composite Index closed at 4136.16 points, above the five-day moving average, with a gain of 0.33% [1] - The total trading volume of A-shares reached 31,181.08 billion yuan [1] - A total of 1,091 A-shares have prices that surpassed the five-day moving average, with notable stocks including Dongfang Risheng, Jinko Solar, and Xinke Mobile, showing divergence rates of 16.59%, 15.85%, and 15.78% respectively [1] Group 2 - The top stocks with significant divergence rates from the five-day moving average include: - Dongfang Risheng (300118) with a price increase of 20.00% and a divergence rate of 16.59% [1] - Jinko Solar (688223) also increased by 20.00% with a divergence rate of 15.85% [1] - Xinke Mobile (688387) rose by 18.41% with a divergence rate of 15.78% [1] - Other notable stocks with divergence rates include: - Jiejia Weichuang (300724) at 20.00% increase and 15.34% divergence [1] - Ruichuang Micro (688002) with a 20.00% increase and 14.83% divergence [1]

每经AI快讯，1月23日，福建板块震荡走高，福建金森涨停，平潭发展、广生堂、乾照光电此前涨停， 海峡创新、龙净环保、中创环保等涨幅居前。 （文章来源：每日经济新闻） ...